Phase 2 Clinical Trial of KH617

• Status: NOT_YET_RECRUITING
• Trial end date: 2030-12-01

Summary

To evaluate the efficacy and safety of KH617 for injection in combination with temozolomide versus investigator's choice therapy or KH617 monotherapy for recurrent glioblastoma

• Phase: PHASE2

Details

• Lead Sponsor: Sichuan Honghe Biotechnology Co., Ltd.
• Treatments: Cisplatin; Platinum